Five things for pharma marketers to know: Friday, December 8, 2017

Share this content:

1. The FDA approved Sunovion Pharmaceuticals' Lonhala Magnair to maintain airflow in adults with chronic obstructive pulmonary disease. It is the first FDA-approved nebulized long-acting muscarinic antagonist to treat COPD. (Medscape)

2. More than 2,000 immunotherapy drugs for cancer are in clinical- or preclinical-stage development, according to a global analysis. Nearly 500 clinical studies began this year, targeting more than 52,000 patients. (Reuters)

3. The FDA issued guidance for 3D-printing products, including recommendations on medical device design, product testing, and quality system requirements. (FDA)

4. Pfizer's experimental breast cancer drug talazoparib was more effective than chemotherapy in preventing the disease from worsening in a Phase-III trial of 431 patients. The PARP inhibitor is set to compete with AstraZeneca's Lynparza. (Endpoints News)

5. The head of Apple Health, Anil Sethi, has left the tech giant to launch medical records startup Ciitizen. The company aims to make it easier for patients to access and share information such as genomic data and lab reports. (CNBC)

Share this content:
Scroll down to see the next article